JUBLPHARMA · Jubilant Pharmova Ltd · Biotechnology & Drugs
JUBLPHARMA · Jubilant Pharmova Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
19.9% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹2,229 Cr
Revenue YoY
PAT YoY
-45.1%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
5.4
P/S (TTM)
1.9
Sector P/E
36.3
Dividend yield
+0.5%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| JUBLPHARMA (this stock) | 43.7 | 5.4 | +4.1% | +5.0% | 0.51 | +0.5% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
stable
MF
8.99% (+0.96pp)
rising 3q
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 09 Mar 2026 | Jubilant Employees Welfare Trust | SELL | 11,304 | ₹92.79 lakh |
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-10-12 | JUBLPHARMA | 1100000 | 1 | WEAK | BULK |
News timeline
- mediummacroeconomictimes.indiatimes.com· 13 Oct 2026, 06:05 amSensex, Nifty fall 0.7% as oil surge erases early gains
- mediumcorporate actionthehindubusinessline.com· 13 Oct 2026, 05:59 amJubilant Pharmova approves ₹800 crore NCD issue
- lowthehindubusinessline.com· 19 Sept 2026, 09:45 pmBandu’s Blockbusters for September 20, 2026
- unknownthehindubusinessline.com· 12 Sept 2026, 08:42 pmBandu’s Blockbusters for September 13, 2026
- unknownthehindubusinessline.com· 12 Sept 2026, 05:33 amJubilant Pharmova’s Spokane facility gets VAI classification from US FDA
- lowthehindubusinessline.com· 24 Aug 2026, 07:20 am20 stocks in focus on Monday: Lenskart, Natco Pharma, Power Grid, GHCL, Sigachi and others
- loweconomictimes.indiatimes.com· 24 Aug 2026, 06:00 amStocks in news: Reliance Industries, Bank of Baroda, Power Grid, NATCO Pharma and JSW Infra
- mediumeconomictimes.indiatimes.com· 11 Aug 2026, 11:25 amJubilant Pharmova shares decline 6% after Q1 profits falls 45% YoY
- mediummacroeconomictimes.indiatimes.com· 15 Jul 2026, 09:20 pmAhead of Market: 10 things that will decide stock market action on Thursday
Concalls & investor presentations
AI-generatedKey takeaway: In the earnings webinar held on May 22, 2026, management reported a 19% year-on-year revenue growth for Q4 FY2026, reaching Rs.2,290 Crores, driven by increases in radiopharma, allergy immunotherapy, CDMO sterile injectables, and generics. EBITDA rose by 2% to Rs.363 Crores, although the EBITDA margin decreased by 272 basis points to 15.7% due to supply shortages in Radiopharmaceuticals. For the full year FY2026, revenue grew by 14% to Rs.8,280 Crores, with EBITDA increasing by 8% to Rs.1,326 Crores. Management noted that normalized PAT for the year grew by 7% to Rs.442 Crores. The discussion included insights on production challenges at CMO Montreal and the anticipated stabilization of EBITDA margins in H2 FY2027. Management also highlighted ongoing investments in manufacturing capacity and the strategic focus on high-value biologics.
The document presented a balanced view of growth and challenges faced by the company.
Sourced from an exchange-filed transcript, dated 27 May 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedJubilant Pharmova Limited's FY2022-23 annual report highlights key corporate governance and business developments, including the demerger of Jubilant Generics Limited's API business under a Scheme of Arrangement approved by the NCLT. The report emphasizes strengthening core businesses like Radiopharmacies, Generics, and APIs, along with capacity expansion in CDMO Sterile Injectables and Drug Discovery Services. The company has robust internal controls and compliance mechanisms, with no defaults in loan repayments or statutory dues. Directors' remuneration, including significant amounts for Mr. Hari S. Bhartia, is disclosed, and the report notes ongoing legal disputes and contingent liabilities, though they are not expected to have a material adverse impact.
- Demerger of Jubilant Generics' API business under a Scheme of Arrangement approved by NCLT on 13 June 2022, effective from 1 July 2022.
- Robust internal controls and compliance mechanisms, with no defaults in loan repayments or statutory dues as of March 31, 2023.
- Directors' remuneration includes ₹11,98,98,702 for Mr. Hari S. Bhartia, including ₹99,00,000 in commission.
- Contingent liabilities and disputes exist, including income tax, customs, and GST claims, but the company believes they won't have a material adverse effect.
- Strengthening core businesses through capacity expansion in CDMO Sterile Injectables and Drug Discovery Services.
Key takeaway: Jubilant Pharmova Limited executed a significant business restructuring through the demerger of its API business, with no major financial defaults or liquidity issues, though it faces ongoing legal disputes that are not anticipated to materially affect its financial position.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Default / Covenant Breach
1 occurrenceRecent (last 12 months)
The company has experienced slight delays in depositing some undisputed statutory dues, though no amounts were outstanding for more than six months at year-end.
Routine disclosures
Contingent Liability
2 occurrencesRecent (last 12 months)
The company has contingent liabilities related to disputed claims, including Income Tax, Customs, Goods and Service Tax, and others, as of 31 March 2026. These liabilities are not acknowledged as debt by the company.
Earlier (1-3 years ago)
The company has contingent liabilities related to disputed claims, including income tax, customs, and GST, with future cash outflows dependent on pending judgments. It is also involved in other disputes, lawsuits, and regulatory investigations, though it believes these will not have a material adverse effect.
Related-Party Transaction
1 occurrenceEarlier (1-3 years ago)
The company has disclosed transactions with related parties, including key management personnel and their related entities, such as Jubilant FoodWorks Limited and Jubilant Ingrevia Limited, involving purchases, recoveries, reimbursements, and investments.
Statutory dues in dispute
1 occurrenceEarlier (1-3 years ago)
The company has undisputed statutory dues for income tax from FY 2008-09 to 2010-11, which are pending before the Assessing Officer.
Management & Board Governance
1 occurrenceRecent (last 12 months)
Mr. Arvind Chokhany and Dr. Ramakrishnan Arul resigned from the Board of Jubilant Pharmova with effect from September 30, 2025.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
4.56% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).